MaxCyte, Inc. (MXCT) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1225673,
    "name": "MaxCyte, Inc.",
    "stock_name": "MaxCyte, Inc.",
    "full_name": "MaxCyte, Inc.",
    "name_url": "stocks-analysis/maxcyte-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.58",
    "chg": 0.01,
    "chgp": "0.64%",
    "dir": 1,
    "prev_price": "1.57",
    "mcapval": "150.32",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US57777K1060",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.16 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/maxcyte-inc-1225673-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is MaxCyte, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-maxcyte-inc-technically-bullish-or-bearish-3545883",
        "imagepath": "",
        "date": "2025-09-20 19:20:44",
        "description": "As of 6 August 2025, the technical trend for MaxCyte, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, indicated by the daily moving averages being bearish and both the KST and MACD on a monthly basis also showing bearish signals. The weekly MACD remains mildly bullish, but this is offset by the overall bearish indicators. Additionally, the stock has significantly underperformed against the S&P 500 over multiple periods, with a year-to-date return of -61.06% compared to the S&P 500's 12.22%...."
      },
      {
        "title": "Is MaxCyte, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-maxcyte-inc-overvalued-or-undervalued-3542554",
        "imagepath": "",
        "date": "2025-09-20 17:55:50",
        "description": "As of 22 March 2022, the valuation grade for MaxCyte, Inc. has moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.15 and a concerning EV to EBITDA ratio of -2.00. Additionally, the Return on Capital Employed (ROCE) stands at a negative 80.39%, further highlighting the company's struggles in generating returns.\n\nIn comparison to its peers, MaxCyte, Inc. has a significantly lower EV to EBITDA ratio of -0.5242 compared to Voyager Therapeutics, Inc. at -0.2378 and bluebird bio, Inc. at -0.7970, suggesting that it is less favorably positioned within the industry. Furthermore, the stock has underperformed relative to the S&P 500, with a year-to-date return of -61.06% compared to the index's 12.22%, reinforcing the notion of its overvaluation amidst a challenging market environment...."
      }
    ],
    "total": 7,
    "sid": "1225673",
    "stock_news_url": "https://www.marketsmojo.com/news/maxcyte-inc-1225673"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is MaxCyte, Inc. technically bullish or bearish?

2025-09-20 19:20:44

As of 6 August 2025, the technical trend for MaxCyte, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, indicated by the daily moving averages being bearish and both the KST and MACD on a monthly basis also showing bearish signals. The weekly MACD remains mildly bullish, but this is offset by the overall bearish indicators. Additionally, the stock has significantly underperformed against the S&P 500 over multiple periods, with a year-to-date return of -61.06% compared to the S&P 500's 12.22%....

Is MaxCyte, Inc. overvalued or undervalued?

2025-09-20 17:55:50

As of 22 March 2022, the valuation grade for MaxCyte, Inc. has moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.15 and a concerning EV to EBITDA ratio of -2.00. Additionally, the Return on Capital Employed (ROCE) stands at a negative 80.39%, further highlighting the company's struggles in generating returns. In comparison to its peers, MaxCyte, Inc. has a significantly lower EV to EBITDA ratio of -0.5242 compared to Voyager Therapeutics, Inc. at -0.2378 and bluebird bio, Inc. at -0.7970, suggesting that it is less favorably positioned within the industry. Furthermore, the stock has underperformed relative to the S&P 500, with a year-to-date return of -61.06% compared to the index's 12.22%, reinforcing the notion of its overvaluation amidst a challenging market environment....

View All News